Clinical effectiveness of apatinib at different doses in patients with advanced gastric cancer as the third-line or further treatment: Results from a post-marketing phase IV study.

doi:10.1200/JCO.2021.39.15_suppl.e16037

	Clinical effectiveness of apatinib at different doses in patients with advanced gastric cancer as the third-line or further treatment: Results from a post-marketing phase IV study.
	Li, Jin ; Qin, Shukui ; Wen, Lu ; Wang, Junsheng ; Deng, Wenying ; Guo, Weijian ; Jia, Tongfu ; Zhao, Qun ; Zhang, Guifang ; He, Yifu
刊名	JOURNAL OF CLINICAL ONCOLOGY
	2021-05-20
卷号	39
ISSN号	0732-183X
DOI	10.1200/JCO.2021.39.15_suppl.e16037
资助项目	Jiangsu Hengrui Pharmaceuticals Co., Ltd
WOS研究方向	Oncology
语种	英语
出版者	LIPPINCOTT WILLIAMS & WILKINS
WOS记录号	WOS:000708120301310
资助机构	Jiangsu Hengrui Pharmaceuticals Co., Ltd
内容类型	期刊论文
源URL	[http://ir.hfcas.ac.cn:8080/handle/334002/126606]
专题	中国科学院合肥物质科学研究院
作者单位	1.Baotou Tumor Hosp, Dept Digest Oncol, Baotou, Peoples R China 2.ZiBo Cent Hosp, Dept Oncol, Zibo, Peoples R China 3.Tongji Univ, Shanghai East Hosp, Dept Oncol, Sch Med, Shanghai, Peoples R China 4.Jinling Hosp, PLA Canc Ctr Nanjing, Nanjing, Peoples R China 5.Shanxi Prov Canc Hosp, Dept Gastroenterol, Taiyuan, Peoples R China 6.Anyang Canc Hosp, Dept Internal Med, Anyang, Peoples R China 7.Zhengzhou Univ, Dept Gastroenterol, Affiliated Canc Hosp, Zhengzhou, Peoples R China 8.Henan Canc Hosp, Zhengzhou, Peoples R China 9.Fudan Univ, Shanghai Canc Ctr, Dept Med Oncol, Shanghai, Peoples R China 10.Hebei Med Univ, Dept Surg, Hosp 4, Shijiazhuang, Hebei, Peoples R China
推荐引用方式 GB/T 7714	Li, Jin,Qin, Shukui,Wen, Lu,et al. Clinical effectiveness of apatinib at different doses in patients with advanced gastric cancer as the third-line or further treatment: Results from a post-marketing phase IV study.[J]. JOURNAL OF CLINICAL ONCOLOGY,2021,39.
APA	Li, Jin.,Qin, Shukui.,Wen, Lu.,Wang, Junsheng.,Deng, Wenying.,...&Sun, Ying.(2021).Clinical effectiveness of apatinib at different doses in patients with advanced gastric cancer as the third-line or further treatment: Results from a post-marketing phase IV study..JOURNAL OF CLINICAL ONCOLOGY,39.
MLA	Li, Jin,et al."Clinical effectiveness of apatinib at different doses in patients with advanced gastric cancer as the third-line or further treatment: Results from a post-marketing phase IV study.".JOURNAL OF CLINICAL ONCOLOGY 39(2021).